Trikafta plus exercise program for adults with cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests how starting Trikafta affects exercise ability and breathing in adults with cystic fibrosis. You may be asked to do supervised breathing and exercise tests to see if Trikafta helps your lung function and stamina.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 19 or older).
- You have cystic fibrosis (CF) with the F508del genetic change (at least one copy).
- You plan to start Trikafta within 30 days of joining the study.
- Your lung function is reduced (FEV1 is under 90% of what’s expected).
- Your body weight is in a safe range (BMI above 16 and below 30).
- You are not currently smoking (or you smoked less than 20 pack-years in the past), and you can read English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study follows people with cystic fibrosis (CF) to understand the long-term impact of CFTR modulator medicines. It may help researchers see how these treatments work over time in real life.
This study tests whether a program combining diet advice and guided exercise can help people with cystic fibrosis who are already on Trikafta improve their lean muscle mass. Participants will be randomly assigned to receive the program or continue their usual care.
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
This study uses MRI scans to monitor lung health in teens and young adults with cystic fibrosis who are taking Trikafta. It aims to find better ways to track how the disease affects the lungs over time.
This study tests whether adding the blood pressure medication losartan can help the standard CF drug Trikafta work better by reducing inflammation. It's for people with CF who still have high sweat chloride levels despite taking Trikafta.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.